Advertisement

Advertisement

ANIP Stock Latest News

ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors

Company AnnouncementsANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors

ANI Pharmaceuticals Signals Strong Growth in 2025 Call

PremiumCompany Announcements

ANI Pharmaceuticals Signals Strong Growth in 2025 Call

24d ago

ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth

PremiumCompany Announcements

ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth

26d ago

ANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98

PremiumThe Fly

ANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98

26d ago

ANI Pharmaceuticals sees FY26 adjusted EPS $8.83-$9.34, consensus $8.64

PremiumThe Fly

ANI Pharmaceuticals sees FY26 adjusted EPS $8.83-$9.34, consensus $8.64

26d ago

ANIP Upcoming Earnings Report: What to Expect?

PremiumPre-EarningsANIP Upcoming Earnings Report: What to Expect?

29d ago

ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim

The Fly

ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim

2M ago

ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook

Company Announcements

ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook

2M ago

ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.

PremiumThe Fly

ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.

2M ago

ANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’

PremiumThe Fly

ANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’

2M ago

ANI Pharmaceuticals Announces Leadership Transition in Board

PremiumCompany Announcements

ANI Pharmaceuticals Announces Leadership Transition in Board

4M ago

ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed

PremiumThe Fly

ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed

4M ago

ANI Pharmaceuticals Highlights November 2025 Financial Strategies

PremiumCompany AnnouncementsANI Pharmaceuticals Highlights November 2025 Financial Strategies

5M ago

ANI Pharmaceuticals price target raised to $115 from $114 at Guggenheim

The Fly

ANI Pharmaceuticals price target raised to $115 from $114 at Guggenheim

5M ago

ANI Pharmaceuticals’ Earnings Call Highlights Record Growth

Company Announcements

ANI Pharmaceuticals’ Earnings Call Highlights Record Growth

5M ago

ANI Pharmaceuticals Reports Record Q3 2025 Results

PremiumCompany Announcements

ANI Pharmaceuticals Reports Record Q3 2025 Results

5M ago

ANI Pharmaceuticals: Strong Commercial Execution and Promising Growth Prospects Reinforce Buy Rating

PremiumRatings

ANI Pharmaceuticals: Strong Commercial Execution and Promising Growth Prospects Reinforce Buy Rating

5M ago

ANI Pharmaceuticals raises FY25 adj. EPS view to $7.37-$7.64 from $6.98-$7.35

PremiumThe Fly

ANI Pharmaceuticals raises FY25 adj. EPS view to $7.37-$7.64 from $6.98-$7.35

5M ago

ANI Pharmaceuticals reports Q3 adjusted EPS $2.04, consensus $1.77

PremiumThe Fly

ANI Pharmaceuticals reports Q3 adjusted EPS $2.04, consensus $1.77

5M ago

ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-EarningsANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

5M ago

ANI Pharmaceuticals price target raised to $90 from $77 at Truist

The Fly

ANI Pharmaceuticals price target raised to $90 from $77 at Truist

6M ago

ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares

Company Announcements

ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >